UK Markets open in 5 hrs 50 mins

argenx SE (ARGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
357.000.00 (0.00%)
At close: 10:40AM EDT
Sign in to post a message.
  • B
    Benjo
    I am raising target to 500 !!
  • A
    Anonymous
    ARGX hit a 52 week high yesterday, then announced a positive opinion from the CHMP on Vyvgart in myasthenia gravis, with EU marketing approval now expected within 60 days.
    Great, upcoming biotech company, great stock to own long.
  • B
    Brian
    Been in ARGX since Nov of 2017 at $22.50, 15,000 shares. It's always been a solid investment. and now paying off big time. Any other longs here?
  • S
    Steve
    The call went extremely well. Price is $225,0000 per patient per year. The label is extremely broad and will allow for many other indications. Approval will be granted in Japan China Israel and EU next year.

    Bottom line is the approval could not have gone better. Every key biotech analyst from all the major brokerage houses were on the call at 6:00pm on a Friday night.

    Just spectacular.
  • B
    Benpattan
    ARGX is well over a year ahead of Momenta (and at least six months ahead of UCB) and has an existing collaboration with J&J. I think the answer is that ARGX doesn’t want to be acquired. It suggests that their recently successful test results for efgartigimod might suggest a larger than expected market size now that J&J has expressed interest on it.
  • A
    Aäron
    On my route to work I drive by the company laboratoria at 'industriepark Zwijnaarde'. Each time I call out a blessing so that the stock may rise. You can al thank me here.
  • B
    Benpattan
    Is anyone else on this board? I pointed out the same upward creep in GLPG and looked what happened. similarly, something is pushing ARGX to daily highs. I, of course, possess ‘massive’ buying power, myself, but my best efforts ceased at $100 when J&J jumped aboard. Come on, people, wakey, wakey. Somebody must know something!
  • e
    eddy
    No brainer investment. In since $40
  • B
    Benpattan
    Biotechs in general and ARGX in particular don’t go with market. Often they do best when the mkt is down. ARGX has a history of treading water for weeks, then riveting up or down on no news. Two weeks ago it was up 13 points inter-day and closed up 9 on good volume. Just take a Valium when it’s going against you. Today it’s up 4, again it’s on no news. There will be news later this year, probably the launch of its first potentially blockbuster drug and maybe some feedback on the joint venture with J&J that owns about 8% of the company. Unfortunately, being a Belgian company, hard news can be scarce and this board almost worthless!
  • B
    Benpattan
    Does anyone understand today’s sell off? (It was up 8 PST Monday). I have read the transcript and other than trial delays due to the virus, can see no smoking gun to cause this. Anybody have a clue?
  • B
    Benpattan
    Boy, they really raised that $500 million easily. Wonder if J&J will increase its 8% stake.
  • D
    Dan’y
    argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
    Regulated Information/Inside Information
    • Independent data monitoring committee confirmed go-forward decision based on evaluation of interim safety as well as efficacy assessments that surpassed pre-defined “GO” threshold
    •  
    • 130 patients targeted for enrollment to support registrational program in CIDP
    •  
    • Management to host conference call today at 2:30 p.m. CET (8:30 a.m. ET)
    February 1, 2021
  • S
    Steve
    Congrats to all longs !!!
  • B
    Benpattan
    Big write-up this week on Seeking Alpha. Nothing new except pointing out that the ‘catalysts’ will be coming next year so we are in limbo for now. Do wish we could get more detail on the blood cancer drug that got $300 million from J&J plus persuaded them to cough up anothr $200 million to buy about 8% of the company. J&J has an existing blockbuster leukaemia drug (shared with ABBV) with sales about $5 billion. Wondering if J&J sees something similar in ARGX’s drug? Very little written on this, emphasis is always concentrated on its major drug that’s due next year.
  • I
    IH8theHeat
    u see big YUGE selling around 3pm BIG YUGE
  • B
    Bioscience NL
    De Europese beurzen diepen door zorgen over de wereldeconomie de verliezen nog uit. 'We zitten al in een berenmarkt', poneert Morgan Stanley. In de Bel20 zijn Solvay en Umicore de grootste dalers.
    De Europese beurzen diepen door zorgen over de wereldeconomie de verliezen nog uit. 'We zitten al in een berenmarkt', poneert Morgan Stanley. In de Bel20 zijn Solvay en Umicore de grootste dalers.
    www.tijd.be
  • g
    gregory s
    anyone know why this is tanking? Big conference on Monday - thought that would be a positive.
  • B
    Bioscience NL
    Nomura/Instinet initiates coverage on argenx SE (NASDAQ: ARGX) with a Buy rating and a price target of $161.00.

    70$ upfront to 161 ,- not bad . Who is selling now ?